Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ASMB files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsAssembly Biosciences stockholders approve 1.2M share increase to equity compensation plan
Filed June 5, 2026 · Period ending June 4, 2026 · ~1 min read
Key Changes
-
medium
Stockholders approved adding 1.2 million shares to the 2018 Stock Incentive Plan, increasing total reserved shares from 1.48 million to 2.68 million for employee equity grants and stock-based compensation.
Item 5.07 verify on EDGAR → -
low
Employee Stock Purchase Plan expanded by 290,000 shares to 515,000 total, allowing increased employee participation but representing additional potential dilution to existing shareholders.
Item 5.07 verify on EDGAR → -
low
Nine directors elected to serve until 2027 annual meeting, all receiving overwhelming stockholder support with over 11 million votes each and minimal opposition.
Item 5.07 verify on EDGAR → -
low
Stockholders approved executive compensation and ratified Ernst & Young LLP as independent auditor for fiscal 2026 in routine annual meeting votes.
Item 5.07 verify on EDGAR →
Summary
Assembly Biosciences held its 2026 annual stockholder meeting on June 4, where shareholders approved significant expansions to the company's equity compensation programs. The most material action was increasing the 2018 Stock Incentive Plan reserve by 1.2 million shares—an 81% expansion that nearly doubles the pool available for employee stock grants.
Combined with the 290,000 share increase to the Employee Stock Purchase Plan, these amendments represent meaningful potential dilution for existing shareholders, though they also provide the company with tools to attract and retain talent in the competitive biotech sector. For retail investors, the key takeaway is increased share dilution ahead.
The equity plan expansion suggests management anticipates significant hiring or retention needs, which could signal growth plans or competitive pressure for talent. Watch the company's next quarterly filing to see how quickly these new shares are deployed and whether headcount or R&D spending increases materially. The routine approval of all directors and executive compensation indicates no significant shareholder dissent on governance matters.
Section-by-Section Diff
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
Assembly Biosciences held its 2026 annual meeting, electing 9 directors and approving executive compensation, auditor selection, and equity plan amendments.
Added in current filing · verify on EDGAR →
The stockholders approved Amendment No. 3 to the 2018 Plan to increase the number of shares reserved for issuance under the 2018 Plan by 1,200,000 shares.
Stockholders approved adding 1,200,000 shares to the 2018 equity incentive plan. This increases the pool available for employee stock compensation and may result in dilution to existing shareholders.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
The stockholders approved the ESPP Amendment No. 2 to increase the number of shares reserved under the ESPP to 515,000 shares.
Stockholders approved increasing the total shares reserved under the Employee Stock Purchase Plan to 515,000 shares. This expands the employee stock purchase program and may cause additional shareholder dilution.
Event · Item 9.01 — Financial Statements and Exhibits
Assembly Biosciences filed amendments to its 2018 Stock Incentive Plan and Employee Stock Purchase Plan.
Show 2 minor / wording changes
Added in current filing · verify on EDGAR →
Amendment No. 3 to Assembly Biosciences, Inc. Amended and Restated 2018 Stock Incentive Plan.
The company amended its 2018 Stock Incentive Plan for the third time. The 8-K does not provide details on what changes were made to the plan, such as share reserve increases or eligibility modifications.
Added in current filing · verify on EDGAR →
Amendment No. 2 to Assembly Biosciences, Inc. Second Amended and Restated 2018 Employee Stock Purchase Plan.
The company amended its Employee Stock Purchase Plan for the second time. The 8-K does not disclose the specific terms or changes made to the ESPP.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 5, 2026 · How we verify